Who are CCP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): COVAX only (1st and 2nd dose), Inactivated SARS-CoV-2 Vaccine (Vero cell）, Inactivated SARS-CoV-2 vaccine, CoronaVac Biofarma COVID-19 Vaccine, Sinopharm BIBP, CoronaVac/CoronaVac.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ccp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CCP — Competitive Intelligence Brief

CCP (CCP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Convalescent plasma. Area: Infectious Disease.

marketed Convalescent plasma SARS-CoV-2 spike protein and other viral antigens Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

CCP (CCP) — Metro Infectious Disease Consultants. CCP is a convalescent plasma product that provides passive immunotherapy through antibodies from recovered COVID-19 patients to treat active SARS-CoV-2 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CCP TARGET	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Inactivated SARS-CoV-2 Vaccine (Vero cell）	Inactivated SARS-CoV-2 Vaccine (Vero cell）	Sinovac Research and Development Co., Ltd.	marketed	inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Inactivated SARS-CoV-2 vaccine	Inactivated SARS-CoV-2 vaccine	Jiangsu Province Centers for Disease Control and Prevention	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
CoronaVac Biofarma COVID-19 Vaccine	CoronaVac Biofarma COVID-19 Vaccine	Dr. Soetomo General Hospital	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Sinopharm BIBP	Sinopharm BIBP	Vaxxinity, Inc.	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
CoronaVac/CoronaVac	CoronaVac/CoronaVac	Institut Pasteur de Tunis	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Convalescent plasma class)

National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
Metro Infectious Disease Consultants · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CCP — Competitive Intelligence Brief. https://druglandscape.com/ci/ccp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab